Wall Street Experts
ver. ZuMIgo(08/25)
Enliven Therapeutics, Inc.
Rachunek Zysków i Strat
Przychody TTM (mln): 0
EBIT TTM (mln): -100
index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
Rok finansowy |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Przychód (mln) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Przychód Δ r/r |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
Marża brutto |
0.0% |
0.0% |
-inf% |
-inf% |
-inf% |
-inf% |
-inf% |
0.0% |
EBIT (mln) |
-9 |
-11 |
-24 |
-9 |
-25 |
-39 |
-84 |
-105 |
EBIT Δ r/r |
0.0% |
19.9% |
125.9% |
-61.4% |
165.7% |
56.7% |
115.3% |
25.2% |
EBIT (%) |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
nan |
Koszty finansowe (mln) |
0 |
0 |
0 |
0 |
0 |
-1 |
0 |
0 |
EBITDA (mln) |
0 |
-11 |
-24 |
-9 |
-25 |
-39 |
-83 |
-105 |
EBITDA(%) |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
nan |
Podatek (mln) |
0 |
0 |
1 |
-0 |
-0 |
0 |
0 |
-0 |
Zysk Netto (mln) |
0 |
-11 |
-23 |
-19 |
-25 |
-38 |
-72 |
-89 |
Zysk netto Δ r/r |
0.0% |
-inf% |
107.0% |
-19.3% |
30.5% |
52.7% |
89.6% |
24.4% |
Zysk netto (%) |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
nan |
EPS |
0.0 |
-1.2 |
-5.43 |
-5.44 |
-10.72 |
-12.08 |
-2.01 |
-1.89 |
EPS (rozwodnione) |
0.0 |
-1.2 |
-5.43 |
-5.44 |
-10.72 |
-12.08 |
-2.01 |
-1.89 |
Ilośc akcji (mln) |
4 |
9 |
4 |
3 |
2 |
3 |
36 |
47 |
Ważona ilośc akcji (mln) |
4 |
9 |
4 |
3 |
2 |
3 |
36 |
47 |
Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |